Alphamab seals $2.2 billion licensing deal with AI biotech
The Chinese drug firm has chosen to partner with an AI specialist rather than Big Pharma on a dual-target cancer therapy, netting an upfront payment of $125 million Key Takeaways:…
Alphamab stake sale could signal harder times ahead
The founder of the cancer drug developer has cashed out part of his holdings after the stock hit a price peak, raising questions about the firm’s earnings outlook Key Takeaways:…
Clinical trials come up short again for Alphamab Oncology
The Chinese pharmaceutical firm has suffered its second clinical setback in a matter of weeks, after its U.S. partner halted trials of a sarcoma drug Key Takeaways: Alphamab Oncology could…
Profit setback for Simcere Pharma in novel drugs quest
The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs Key Takeaways: Simcere Pharmaceutical holds a 9% stake in…
RELATED ARTICLES
-
Mega licensing deal lifts 3SBio profits but core sales slip
-
Biokin’s world-first bispecific ADC hits milestones, speeding commercialization
688506.SHG
- Innovent’s $10.5 billion deal marks new model for China drugmakers
- Jacobio Pharma poised to turn a profit from precision cancer drugs
- A healthy return: drug spin-off nets Keymed up to $320 million
- Insilico revenue soars above $100 million on AI drug partnerships
-
InnoCare hits profit milestone, enters new phase with global expansion, strong pipeline
9969.HK688428.SHG
